IGF-1 LR3 Side Effects: What the Evidence Actually Shows

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

IGF-1 LR3 side effects — what the evidence actually shows

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

IGF-1 LR3 side effects have never been measured in a human being — the most important fact on this page. No published clinical trial has administered IGF-1 LR3 to a person. Every adverse-event rate you will read anywhere, including here, belongs to a different molecule: recombinant human IGF-1 (rhIGF-1, mecasermin, Increlex), studied in children with growth disorders. LR3 binds IGF binding proteins poorly, which is precisely why borrowing mecasermin’s numbers is unreliable in both directions.

Quick Answer: What the Evidence Actually Shows

There is no human side-effect data for IGF-1 LR3 itself. The closest profile belongs to rhIGF-1 (mecasermin) in a European registry of 195 treated children, where the most frequent targeted treatment-emergent adverse events were hypoglycemia (17.6%), lipohypertrophy (10.6%), tonsillar hypertrophy (7.4%), injection site reactions (6.4%), and headache (5.9%), with 61 serious adverse events in 31 patients (16.5%) — mecasermin, not LR3 (PMID 25824333). Animal work on LR3 itself found suppressed insulin secretion in fetal sheep and suppressed growth hormone in pigs. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience: Zero Humans on LR3, 346 on rhIGF-1

There is no monitored human experience of IGF-1 LR3 to summarize: no investigator has ever recorded a blood glucose or an adverse event on this molecule in a person. What exists belongs to a relative: the Global Increlex Growth Forum Database held 346 patients on rhIGF-1 (mecasermin) at its 03 April 2025 cut-off, where hypoglycemia is the most frequent targeted adverse event (PMID 42341624).

Those patients were children with severe growth disorders — in Laron syndrome, childhood height standard deviation scores of -6 to -12 — treated for years with a diagnosis, clinician-selected dosing, glucose monitoring and a mandated registry behind them. None of that ships with a research vial.

Compiled from the published literature (PMID 42341624, PMID 25824333, PMID 37579214) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is IGF-1 LR3?

IGF-1 LR3 — Long R3 IGF-I in the literature — is an engineered analogue of insulin-like growth factor 1, described by the researchers who infuse it as “an IGF-1 analog with low affinity for the IGF binding proteins and high affinity for the IGF-1 receptor” (PMID 33938236). Built as a research reagent, it has never been given to a human in a published trial. What does have a human record is recombinant human IGF-1 — mecasermin, sold as Increlex — approved in the US and EU for growth failure in children with severe primary IGF-I deficiency (PMID 18481900). Mecasermin is native-sequence IGF-1; LR3 is not — the substitution the marketing runs on, as in listings beside our muscle-mass peptide overview.

How It Works — and Why the Comparison Breaks

Binding proteins hold circulating IGF-1 and control how much reaches the IGF-1 receptor; the LR3 modification deliberately weakens that binding so the analogue slips the buffer (PMID 39679943) — the selling proposition, and the reason mecasermin’s rates cannot transfer across. Analogues that bind poorly to IGF binding proteins stimulate growth in the rat but inhibit growth in the pig, and a four-day infusion of Long [R3] IGF-I into finisher pigs at 180 micrograms/kg/day decreased average daily gain, food intake, and plasma IGFBP-3, IGF-I and insulin, while mean plasma growth hormone fell by 23% and the area under the GH peaks was reduced by 60% (PMID 9488001).

KEY TAKEAWAY

Weak binding-protein affinity is why IGF-1 LR3 is potent, and why extrapolating from mecasermin is unreliable in both directions: the analogue could carry more risk than rhIGF-1, less, or a different risk entirely. No published human study has settled which.

The Studies That Exist

Two bodies of evidence carry this page. The human evidence is all rhIGF-1: the European Increlex Growth Forum Database reported safety on 195 enrolled children (PMID 25824333), analyzed hypoglycemia across 306 enrolled patients (PMID 37579214), outcomes in 242 children (PMID 33434161), and 346 patients at the 03 April 2025 cut-off (PMID 42341624), alongside a mecasermin phase 1 in 12 girls with MECP2 mutations and a phase 2 trial of rhIGF-1/rhIGFBP-3 in preterm infants. The LR3 evidence is all animal: one-week infusions into normal fetal sheep (n = 8 vs control n = 9) and growth-restricted fetal sheep (n = 7 vs vehicle n = 7), plus the pig study.

Hypoglycemia: The Defining Adverse Event

In the European Increlex registry of 195 children, hypoglycemia was the most frequent targeted treatment-emergent adverse event of rhIGF-1 (mecasermin) therapy, in 17.6% of patients, with young age and Laron syndrome as predictors — but not rhIGF-1 dose (PMID 25824333).

Bar chart of the most frequent targeted adverse events in 195 children treated with rhIGF-1 (mecasermin) in the EU Increlex Growth Forum Database registry: hypoglycemia 17.6%, lipohypertrophy 10.6%, tonsillar hypertrophy 7.4%, injection-site reactions 6.4%, headache 5.9%. IGF-1 LR3 itself has never been trialed in people.
Chart: the five most frequent targeted treatment-emergent adverse events in the 2008–2013 EU Increlex Growth Forum Database registry of 195 children on rhIGF-1 (mecasermin), plotted from the published rates (PMID 25824333). These are mecasermin numbers in children with growth failure, not IGF-1 LR3 numbers — no LR3 human dataset exists to plot.

Among 306 registry patients on rhIGF-1, the 80 with at least one hypoglycemia adverse event differed from the 224 without: lower mean age at treatment start (8.7 years vs 9.8 years), more frequent Laron syndrome (27.5% vs 10.3%), and a history of hypoglycemia (18.8% vs 4.5%). Prior hypoglycemia (OR 0.25; P = .002) and Laron syndrome (OR 0.36; P = .004) predicted future events, and total hypoglycemia adverse events per patient per treatment year was 0.11, with serious ones at 0.01 (PMID 37579214). The counterweight is the Rett phase 1: mecasermin in 12 girls across a 4-week multiple ascending dose period and a 20-week open-label extension, 12 completing the escalation and 10 the entire study, without evidence of hypoglycemia or serious adverse events (PMID 24623853).

PERSONAL OBSERVATION — PI EDITORIAL

Reading the registry papers beside the LR3 animal work, what struck us was the direction of the surprises. The registry found hypoglycemia risk tracked who the patient was — age, Laron syndrome, prior hypoglycemia — not the rhIGF-1 dose. The sheep work found LR3 lowered insulin secretion, and kept lowering it in islets removed from the animal. Both contradict the forum model.

Tissue Overgrowth: Lipohypertrophy and Tonsillar Hypertrophy

The next two targeted adverse events get little attention in research-market discussion, and both are growth in the wrong place. In 195 children on rhIGF-1 (mecasermin), lipohypertrophy occurred in 10.6% and tonsillar hypertrophy in 7.4% (PMID 25824333) — thickened fatty tissue at reused injection sites, and enlarged lymphoid tissue in the throat. IGF-1 LR3 itself has no published tissue data beyond a week in any species.

Injection-Site Reactions

The registry is precise: injection site reactions were reported in 6.4% of the 195 children treated with rhIGF-1 (mecasermin) (PMID 25824333), recorded during routine rhIGF-1 therapy.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Site rotation is the standard answer to repeated subcutaneous dosing — the 10.6% lipohypertrophy rate in the rhIGF-1 registry is what accumulates when tissue is reused
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol
  • Our bacteriostatic water guide and reconstitution protocol cover handling

Beyond Blood Sugar: Serious Events and the Preterm Signal

Headache rounds out the registry’s targeted list at 5.9%, and the serious end deserves quoting exactly: 61 serious adverse events, 37 related to rhIGF-1 therapy, in 31 patients (16.5%) (PMID 25824333). A separate analysis of 242 children on rhIGF-1 found treatment-emergent adverse events in 65.3% of patients, hypoglycaemia most common (PMID 33434161).

The preterm trial adds the most sobering number. Infants born at 23 0/7 to 27 6/7 weeks of gestation received rhIGF-1/rhIGFBP-3 by continuous intravenous infusion or standard neonatal care; fatal serious adverse events were reported in 19.7% of treated infants (12/61) and 11.7% of control infants (7/60) (PMID 30471715). Baseline mortality there is high — the control arm shows it — and the rhIGF-1/rhIGFBP-3 results were no effect on retinopathy of prematurity plus a 53% decrease in severe bronchopulmonary dysplasia in the full analysis set (21.3% vs 44.9%). That was rhIGF-1 with its binding protein, infused intravenously into extremely preterm infants; it models nothing sold in a vial.

What Users Report: Self-Reported Effects From Reddit

Every human adverse-event figure on this page comes from mecasermin, not from IGF-1 LR3. The only descriptions of the analog itself in people are self-reports, and IGF-1 LR3 has an unusually long Reddit history because bodybuilders were injecting it a decade before the current peptide boom. We searched Reddit on September 4, 2026, found 31 relevant posts from 2018 to 2026, and read the comment threads of six, across r/Peptides, r/BodyHackGuide, r/PeptideGuide and r/steroids. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified; in this community the users themselves say much of what is sold as LR3 is something else. These reports can flag a pattern. They cannot establish frequency, causation or a safe dose.

Hypoglycemia is treated as an expected feature, not a side effect. The community’s dosing advice, repeated in a 15-comment r/PeptideGuide guide, is to start low and raise the dose until you feel the hypoglycemia, then back off; users are told to eat carbohydrates around injections (thread). When a 20-year-old whose father has type 2 diabetes asked about a four-week cycle, the most-upvoted reply told him to post his IGF-1, HbA1c and fasting insulin first and, with that family history, to skip it; another warned that it can cause insulin resistance if not dosed or cycled right (r/BodyHackGuide). Compare that with the registry data above, where hypoglycemia in children on the approved product is the adverse event clinicians monitor most closely.

The most alarming thread is a liver scare, and it is confounded. A 23-year-old on 20 to 60 mcg a day for five to six weeks, using no other compounds, spent three days in hospital with liver injury after taking well above the recommended amount of paracetamol-codeine for a tooth infection; he wrote that clinicians said his liver reacted worse than the paracetamol dose alone would explain, and asked whether LR3 was involved. One reply asserted that LR3 is linked to elevated liver enzymes and organ enlargement; a later, more careful reply judged the timing fit paracetamol toxicity and that LR3 alone would not cause liver failure (thread). The same poster reported about two weeks of a sore, achy upper back, shoulders and neck at the start of each of two cycles. In the same thread another user reported significant tension headaches and fatigue on LR3 and was pointed toward blood sugar.

Connective tissue and growth complaints appear as scattered single reports. A user who ran 40 mcg a day for four weeks alongside a growth-hormone secretagogue stack reported clear strength and muscle gains and carpal tunnel symptoms (r/Peptides). A commenter on a long lifter’s write-up said a brief run did little except damage his tendons (thread). In a 2022 thread on “receptor grade” LR3, experienced users described daily growth as an unpleasant sensation, with odd cortisol effects, and, for one, prolactin and anxiety increases that made him abandon IGF-1 and GH peptides for prescription growth hormone (thread). The lifter who wrote the long guide noted that acetic-acid-reconstituted LR3 burns badly on injection. Organ enlargement is invoked constantly as a fear, and we found no post describing it as an experienced event.

Suppression is the concern nobody measures. A 2026 poster pointed out that an IGF-1 receptor agonist should feed back on the pituitary and suppress natural growth hormone, and that the community barely mentions it; a reply noted that young users think the only risks are hypoglycemia and unwanted growth. Standard IGF-1 blood tests, another thread notes, do not detect LR3, so users cannot even confirm exposure.

Adulteration is assumed by the users themselves. The author of the most-upvoted guide divides LR3 buyers into thirds: those who see two good weeks then a fall-off, those who get nothing or get hungry or notice testicular changes, whom he says received GHRP-6 or hCG relabeled as LR3, and those who get pumps and nothing else; he insists anything cheap is fake. Another user ran 100 mcg a day through three vials and got a pump and no gains (thread).

HOW TO READ SELF-REPORTS

The self-reports and the registry data agree on one thing: low blood sugar is the effect to expect. Where they part ways is discipline. Children on mecasermin have hypoglycemia logged per patient-year with predictive factors; adults on LR3 are told to titrate until they feel it. Everything else here, from the liver scare to carpal tunnel, is a single anonymous report about a product that a standard lab test could not confirm was IGF-1 LR3 at all.

When Effects Appear — and What Nobody Measured

No published data supports a week-by-week IGF-1 LR3 side-effect timeline, and anyone selling one invented it. On the rhIGF-1 side, hypoglycemia recurs at 0.11 events per patient per treatment year, with very few events per patient over a course of therapy (PMID 37579214, PMID 42341624). On the LR3 side, the whole published time base is one week in fetal sheep and four days in pigs, and what changed within it was metabolic rather than symptomatic: lower insulin and glucose, reduced glucose-stimulated insulin secretion, suppressed growth hormone, decreased amino acids (PMID 33938236, PMID 39679943).

Long-Term Safety: Years of rhIGF-1, Days of LR3

Mecasermin has the long-run record most research-market compounds never get: 76 children received subcutaneous mecasermin for a mean 4.4 years (range 0.04-12.5 years), with mean growth velocities above baseline for up to 8 years (PMID 18481900), and EMA approval required data up to 5 years post-treatment, which is why the 346-patient registry exists (PMID 42341624). For IGF-1 LR3 the longest published exposure in any species is one week: no chronic data, no human data at all — the absence of anyone looking, not a clean record. The same borrowed-file pattern runs through much of peptides marketed for aging and peptides marketed to athletes.

Who the Studies Enrolled

Safety numbers describe the population that produced them. The registries enrolled children with severe primary IGF-1 deficiency — 84.6% of the 306 patients (PMID 37579214) — a group defined by not making enough IGF-1. Nobody here is a healthy adult with a normal IGF-1 axis, and the pig study warns against assuming that doesn’t matter: in an animal with an intact GH axis, Long [R3] IGF-I suppressed that axis and reduced growth (PMID 9488001).

Managing Risk: What the Registries Did

The management strategy in the published record is monitoring and patient selection, not a mitigation stack. The Eu-IGFD authors state it plainly: hypoglycemia occurs more frequently in patients with prior history of hypoglycemia and/or Laron syndrome, and these patients should be carefully monitored throughout treatment (PMID 37579214). That is an instruction to endocrinologists treating diagnosed children on rhIGF-1, not a protocol for anyone else. No co-medication scheme appears in these abstracts, so none appears here. What every record above shares is a clinician with glucose measurements — the component a purchase cannot replicate.

Dose and Side Effects: What the Studies Administered

What investigators gave: the mecasermin approval trial used 0.12 mg/kg subcutaneously twice daily in children (PMID 18481900); the Rett phase 1 administered 40-120 μg/kg twice daily (PMID 24623853); the preterm trial infused rhIGF-1/rhIGFBP-3 at 250 µg/kg/24 hours intravenously (PMID 30471715). For LR3 itself, fetal sheep received 6.6 µg·kg-1·h-1 (normal) and 1.17 ± 0.12 μg·kg-1·h-1 (growth-restricted), and pigs 180 micrograms/kg/day (PMID 39679943, PMID 9488001) — species and routes with no bearing on a person.

DID YOU KNOW

The four-day Long [R3] IGF-I infusion in pigs cut mean plasma growth hormone by 23% and the area under the GH peaks by 60%, while plasma IGFBP-3, IGF-I and insulin all fell (PMID 9488001) — the analogue suppressed the animal’s own growth axis.

Combined With Other Compounds

Exactly one published combination experiment involves this analogue, and it is in pigs: co-administering porcine growth hormone at 30 micrograms/kg/day with Long [R3] IGF-I had no interactive effect on growth performance, plasma insulin, IGFBP-3 and IGF-I remained suppressed, and the area under the GH peaks was not restored (PMID 9488001). No human combination has been studied, because the single agent has not been. The closest designed combination here points the other way — rhIGF-1 complexed with rhIGFBP-3 in the preterm trial (PMID 30471715), restoring the partnership LR3 was engineered to escape.

How IGF-1 LR3 Compares to rhIGF-1

Every comparison here is cross-study and cross-species — different populations, durations and endpoints, a real limitation. rhIGF-1 (mecasermin) in children has a measured adverse-event profile and a measured benefit: first-year height velocity of 6.9 ± 2.2 cm/year (n = 144) alongside those registry rates (PMID 25824333). IGF-1 LR3 has no corresponding column. The nearest head-to-head is in pigs, both infused at 180 micrograms/kg/day: native IGF-I decreased plasma insulin and mean GH but left average daily gain and feed intake unchanged, while Long [R3] IGF-I decreased gain, food intake, IGFBP-3, IGF-I and insulin (PMID 9488001) — the strongest argument against treating them as interchangeable. The market runs on that substitution; Adamax is sold on Semax’s evidence base and Adalank on Selank’s.

Where the Data Stops: The Research-Vial Reality

This compound has a supply-chain problem documented in a peer-reviewed journal. Analysts at the German Sport University Cologne examined a black-market injection vial by immunoaffinity purification, nano-UPLC, high-resolution mass spectrometry and ELISA, and identified Long-R³-IGF-I carrying a His₆-tag attached to the C-terminus by the linker amino acids Leu-Glu — a purification handle used when proteins are made for biochemical studies (PMID 20675162).

Their conclusion: His-tags are normally removed enzymatically when attached to the N-terminus, the effects of His-tagged Long-R³-IGF-I in humans have not been elucidated or described, and the product may rather be a by-product from biochemical studies than something synthesized for injection purposes. That is not a purity complaint about a percentage; it is a different molecule than the label claims, in an injection vial. The rest stacks on top: no identity guarantee without a batch-matched COA, reconstitution arithmetic left to the buyer using bacteriostatic water and our peptide calculator, and no medical monitoring. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

The His-tag case sets the verification standard, because the failure mode was identity rather than potency: a purity percentage would not have caught it, while mass spectrometry of the intact and trypsinated substance did (PMID 20675162). So: batch-matched documentation naming compound and quantity, third-party testing with a verifiable report number, and identity confirmed by mass spectrometry — our guides on reading a certificate of analysis and peptide mass spectrometry cover what those prove. Treat any listing citing Increlex results or “clinically studied” language for an LR3 vial as a red flag, not a credential. (Disclosure: some links here are affiliate links; they don’t change what we report.) Our scam defense guide and lab testing hub cover the rest.

US Regulatory Status

Mecasermin (rhIGF-1) is an approved drug — cleared in the US for long-term treatment of growth failure in children with severe primary IGF-I deficiency or with GH gene deletion who have developed neutralizing antibodies to GH, and in the EU for the same population (PMID 18481900) — and its European authorization required registry collection of on-therapy and post-treatment data (PMID 42341624), the mechanism that produced most numbers here. IGF-1 LR3 has none of that: not approved as a medicine anywhere, never evaluated by a regulator for identity, purity or safety, and sold strictly for non-human research use.

PERSONAL OBSERVATION — PI EDITORIAL

In listings we’ve reviewed, IGF-1 LR3 is described with more confidence than almost any compound we cover, and the confidence is borrowed. Strip out every sentence actually about mecasermin or native IGF-1, and what remains in humans is one 2010 case report of a His-tagged reagent found inside an injection vial.

Frequently Asked Questions

What are the most common IGF-1 LR3 side effects?

No human rates exist for IGF-1 LR3. The nearest profile is rhIGF-1 (mecasermin) in a registry of 195 children: hypoglycemia 17.6%, lipohypertrophy 10.6%, tonsillar hypertrophy 7.4%, injection site reactions 6.4%, headache 5.9% — mecasermin numbers, not LR3 numbers.

Does IGF-1 LR3 cause hypoglycemia?

Unknown for LR3 specifically. Hypoglycemia is the most frequent targeted adverse event of rhIGF-1 (mecasermin) therapy — 17.6% of patients in the 195-child registry, and 0.11 events per patient per treatment year in the 306-patient analysis. In fetal sheep, IGF-1 LR3 lowered plasma insulin and glucose.

Has IGF-1 LR3 ever been tested in humans?

Not in any published clinical trial. The only human-adjacent publication is a 2010 case report in which a black-market injection vial was found to contain Long-R3-IGF-I with a His6-tag on the C-terminus — a form the authors noted had not been studied in humans. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

Is IGF-1 LR3 the same as mecasermin or Increlex?

No. Mecasermin (Increlex) is native-sequence recombinant human IGF-1, approved for growth failure in severe primary IGF-I deficiency. IGF-1 LR3 is an engineered analogue that binds the IGF binding proteins poorly. In pigs infused at the same 180 micrograms/kg/day, the two produced different effects on growth.

What did the animal studies show about IGF-1 LR3?

In late-gestation fetal sheep, a one-week infusion lowered plasma insulin and glucose and reduced glucose-stimulated insulin secretion, an effect persisting in isolated islets. In growth-restricted fetal sheep it did not improve growth. In pigs, a four-day infusion cut mean plasma growth hormone by 23%.

Is IGF-1 LR3 safe?

The question has no evidence-based answer: IGF-1 LR3 has never been measured in a human. The absence of reported human side effects reflects the absence of surveillance, not a clean record — and the one analysis of a market vial found a His-tagged reagent whose effects in humans have not been elucidated or described.

Glossary of Terms

  • IGF-1 LR3 (Long R3 IGF-I): an engineered IGF-1 analogue with low binding-protein affinity and high IGF-1 receptor affinity; a reagent, not a drug.
  • IGF binding proteins (IGFBPs): carriers that bind circulating IGF-1 and control how much reaches the receptor; IGFBP-3 was measured in the pig study.
  • Mecasermin (Increlex): native-sequence recombinant human IGF-1, approved for growth failure in severe primary IGF-I deficiency; source of every human rate here.
  • SPIGFD: severe primary insulin-like growth factor-1 deficiency, carried by 84.6% of registry patients.
  • Laron syndrome: the most severe primary IGF-I deficiency phenotype, from GH receptor gene defects; predicts hypoglycemia on rhIGF-1.
  • GSIS (glucose-stimulated insulin secretion): the insulin response to a glucose challenge; reduced by IGF-1 LR3 in fetal sheep and isolated islets.
  • His-tag: a histidine sequence added during synthesis to simplify purification, normally removed enzymatically; found attached in a market vial.

References